Phase II Trial of Altretamine for Consolidation of Clinical Complete Response in Patients with Stage III Epithelial Ovarian Cancer

Pretreatment CA-125 and risk of relapse in advanced ovarian cancer

M Markman;PY Liu;M Rothenberg;BJ Monk;M Brady;DS Alberts Journal of Clinical Oncology 24(9):1454-1458

Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group

DS Alberts;C Jiang;PY Liu;SP Wilcynski;M Markman;ML Rothenberg International Journal of Gynecologic Cancer 14:224-228

Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326)

ML Rothenberg;PY Liu;S Wilczynski;EV Hannigan;SA Weiner;GR Weiss;VJ Hunter;J Chapman;AD Tiersten;P Kohler;DS Alberts Gynecologic Oncology 82:317-322

Phase II trial of oral alretamine for women with stage III epithelial ovarian cancer in clinical complete remission: a Southwest Oncology Group study (S9326)

ML Rothenberg;PY Liu;SA Weiner;V Hunter;A Tiersten;PC Kohler;EV Hannigan;S Wilczynski;DS Alberts Gynecologic Oncology 76(2):263-264(#126)

Altretamin (Hexalen) consolidation for patients with stage III epithelial ovarian cancer in clinical complete remission: a Southwest Oncology Group trial (S9326)

DS Alberts;ML Rothenberg;PY Liu;SA Weiner;V Hunter;A Tiersten;PC Kohler;EV Hannigan;S Wilczynski Proc of the American Society of Clinical Oncology 19:384a(#1520)